DTIL - Precision BioSciences, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Durham,
United States
Type: Equity
DTIL price evolution
DTIL
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $116.68 | $122.23 | $137.79 | $158.13 |
| Short term investments | $11.9 | $11.69 | ||
| Net receivables | $0.9 | $3.51 | $0.65 | $0.69 |
| Inventory | ||||
| Total current assets | $136.36 | $145.85 | $147.86 | $169.02 |
| Long term investments | $8.2 | $7.47 | $8.69 | $9.97 |
| Property, plant & equipment | $14.6 | $9.81 | $22.97 | $21.24 |
| Goodwill & intangible assets | $0.4 | $0.98 | $1.55 | $1.52 |
| Total noncurrent assets | $23.42 | $18.49 | $33.83 | $35.48 |
| Total investments | $20.09 | $19.15 | $8.69 | $9.97 |
| Total assets | $159.78 | $164.34 | $181.7 | $204.5 |
| Current liabilities | ||||
| Accounts payable | $25.38 | $22.9 | $23.1 | $0.7 |
| Deferred revenue | $95.12 | $101.34 | $111.89 | $131.03 |
| Short long term debt | $1.13 | $1.49 | $2.5 | $2.09 |
| Total current liabilities | $49.99 | $50.62 | $56.4 | $46.86 |
| Long term debt | $7.72 | $3.17 | $24.5 | |
| Total noncurrent liabilities | $90.93 | $84.66 | $91.26 | $117.47 |
| Total debt | $8.86 | $1.49 | $5.67 | $26.6 |
| Total liabilities | $140.92 | $135.28 | $147.66 | $164.32 |
| Shareholders' equity | ||||
| Retained earnings | -$489.63 | -$473.34 | -$465.26 | -$453.37 |
| Other shareholder equity | $34.04 | |||
| Total shareholder equity | $18.86 | $29.06 | $34.04 | $40.18 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $116.68 | $189.58 | $143.66 | $89.8 |
| Short term investments | $11.9 | |||
| Net receivables | $0.9 | $0.72 | $0.49 | $10 |
| Inventory | ||||
| Total current assets | $136.36 | $199.1 | $161.75 | $105.56 |
| Long term investments | $8.2 | $11.98 | $13.72 | |
| Property, plant & equipment | $14.6 | $23.16 | $29.33 | $41.5 |
| Goodwill & intangible assets | $0.4 | $1.35 | $2.05 | $1.37 |
| Total noncurrent assets | $23.42 | $39.06 | $49.74 | $44.59 |
| Total investments | $20.09 | $11.98 | $13.72 | |
| Total assets | $159.78 | $238.17 | $211.5 | $150.16 |
| Current liabilities | ||||
| Accounts payable | $25.38 | $1.23 | $1.14 | $0.79 |
| Deferred revenue | $95.12 | $139.06 | $98.26 | $84.16 |
| Short long term debt | $1.13 | $2.04 | $1.82 | $1.93 |
| Total current liabilities | $49.99 | $59.66 | $35.98 | $42.83 |
| Long term debt | $7.72 | $22.22 | $7.29 | $8.59 |
| Total noncurrent liabilities | $90.93 | $118.07 | $84.35 | $62.9 |
| Total debt | $8.86 | $27.04 | $9.11 | $10.52 |
| Total liabilities | $140.92 | $177.74 | $120.33 | $105.73 |
| Shareholders' equity | ||||
| Retained earnings | -$489.63 | -$428.31 | -$316.68 | -$286.07 |
| Other shareholder equity | -$0 | $0.05 | ||
| Total shareholder equity | $18.86 | $60.43 | $91.17 | $44.42 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7.04 | $13.12 | $19.79 | $8.78 |
| Cost of revenue | ||||
| Gross Profit | $7.04 | $13.12 | $19.79 | $8.78 |
| Operating activities | ||||
| Research & development | $13.39 | $15.85 | $21.95 | $22.16 |
| Selling, general & administrative | $8.54 | $9.63 | $9.83 | $11.09 |
| Total operating expenses | $21.93 | $25.48 | $31.78 | $33.24 |
| Operating income | -$14.89 | -$12.36 | -$11.99 | -$24.46 |
| Income from continuing operations | ||||
| EBIT | -$15.71 | -$7.5 | -$11.34 | -$24.54 |
| Income tax expense | ||||
| Interest expense | $0.58 | $0.58 | $0.55 | $0.52 |
| Net income | ||||
| Net income | -$16.29 | -$8.08 | -$11.89 | -$25.06 |
| Income (for common shares) | -$16.29 | -$8.08 | -$11.89 | -$25.06 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $48.73 | $25.1 | $115.53 | $24.29 |
| Cost of revenue | ||||
| Gross Profit | $48.73 | $25.1 | $115.53 | $24.29 |
| Operating activities | ||||
| Research & development | $53.38 | $83.94 | $115.24 | $98.06 |
| Selling, general & administrative | $39.09 | $41.52 | $39.69 | $36.05 |
| Total operating expenses | $92.46 | $125.46 | $154.93 | $134.11 |
| Operating income | -$43.74 | -$100.37 | -$39.4 | -$109.83 |
| Income from continuing operations | ||||
| EBIT | -$59.09 | -$110.53 | -$30.47 | -$109.01 |
| Income tax expense | ||||
| Interest expense | $2.23 | $1.11 | $0.13 | |
| Net income | ||||
| Net income | -$61.32 | -$111.64 | -$30.6 | -$109.01 |
| Income (for common shares) | -$61.32 | -$111.64 | -$30.6 | -$109.01 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$16.29 | -$8.08 | -$11.89 | -$25.06 |
| Operating activities | ||||
| Depreciation | $1.56 | $2.04 | $2.38 | $2.28 |
| Business acquisitions & disposals | $8 | |||
| Stock-based compensation | $2.97 | $3.1 | $3.87 | $4.09 |
| Total cash flows from operations | -$8.42 | -$23.09 | -$21.13 | -$31.46 |
| Investing activities | ||||
| Capital expenditures | $0.06 | -$0.39 | -$1.01 | -$0.52 |
| Investments | ||||
| Total cash flows from investing | $0.04 | $7.56 | -$1.06 | -$0.72 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.83 | -$0.03 | $1.85 | $0.74 |
| Net borrowings | ||||
| Total cash flows from financing | $2.83 | -$0.03 | $1.85 | $0.74 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$5.55 | -$15.56 | -$20.34 | -$31.44 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$61.32 | -$111.64 | -$30.6 | -$109.01 |
| Operating activities | ||||
| Depreciation | $8.26 | $9 | $10.2 | $9.81 |
| Business acquisitions & disposals | $8 | |||
| Stock-based compensation | $14.04 | $19.2 | $16.51 | $13.79 |
| Total cash flows from operations | -$84.11 | -$45.75 | -$10.85 | -$87.39 |
| Investing activities | ||||
| Capital expenditures | -$1.85 | -$3.32 | -$5.05 | -$5.03 |
| Investments | ||||
| Total cash flows from investing | $5.83 | -$3.32 | -$5.8 | -$5.03 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $5.39 | $74.79 | $68.06 | $1.33 |
| Net borrowings | $19.8 | $2.46 | ||
| Total cash flows from financing | $5.39 | $94.98 | $70.52 | $1.33 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$72.9 | $45.91 | $53.87 | -$91.09 |
News
Fundamentals
| Market cap | $40.47M |
|---|---|
| Enterprise value | -$67.35M |
| Shares outstanding | 4.16M |
| Revenue | $48.73M |
|---|---|
| EBITDA | -$50.83M |
| EBIT | -$59.09M |
| Net Income | -$61.32M |
| Revenue Q/Q | -33.59% |
| Revenue Y/Y | 94.15% |
| P/E ratio | -0.66 |
|---|---|
| EV/Sales | -1.38 |
| EV/EBITDA | 1.32 |
| EV/EBIT | 1.14 |
| P/S ratio | 0.83 |
| P/B ratio | 2.15 |
| Book/Share | 4.53 |
| Cash/Share | 28.02 |
| EPS | -$14.73 |
|---|---|
| ROA | -34.53% |
| ROE | -200.81% |
| Debt/Equity | 7.47 |
|---|---|
| Net debt/EBITDA | -0.48 |
| Current ratio | 2.73 |
| Quick ratio | 2.73 |